

Giuliano Polichetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3847545/publications.pdf>

Version: 2024-02-01

13
papers

675
citations

932766

10
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

1318
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of travel restriction on PM10 concentrations in Naples: One year of experience. Atmospheric Environment, 2017, 151, 12-16.	1.9	5
2	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. Critical Reviews in Environmental Science and Technology, 2013, 43, 752-774.	6.6	10
3	Effects of Ambient Air Pollution on Birth Outcomes: An Overview. Critical Reviews in Environmental Science and Technology, 2013, 43, 1223-1245.	6.6	15
4	Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options. Current Opinion in Pharmacology, 2011, 11, 378-394.	1.7	73
5	Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors. Current Drug Metabolism, 2011, 12, 253-267.	0.7	24
6	Cigarette Smoke Condensate Causes a Decrease of the Gene Expression of Cu ²⁺ /Zn Superoxide Dismutase, Mn Superoxide Dismutase, Glutathione Peroxidase, Catalase, and Free Radical-Induced Cell Injury in SH-SY5Y Human Neuroblastoma Cells. Neurotoxicity Research, 2011, 19, 49-54.	1.3	20
7	Evaluation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrology Dialysis Transplantation, 2011, 26, 3019-3025.	0.4	25
8	Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 121-124.	0.7	41
9	Absence of Pharmacokinetic Interference of Moxifloxacin on Cyclosporine and Tacrolimus in Kidney Transplant Recipients. Journal of Clinical Pharmacology, 2010, 50, 576-580.	1.0	8
10	Effects of particulate matter (PM10, PM2.5 and PM1) on the cardiovascular system. Toxicology, 2009, 261, 1-8.	2.0	265
11	EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundamental and Clinical Pharmacology, 2009, 23, 617-624.	1.0	30
12	A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatology Research, 2007, 37, 410-415.	1.8	139
13	Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients. European Journal of Clinical Pharmacology, 2006, 62, 605-612.	0.8	20